Plus Therapeutics Stock Technical Analysis
| PSTV Stock | USD 0.23 0.01 4.17% |
As of the 5th of February, Plus Therapeutics holds the Risk Adjusted Performance of (0.09), variance of 48.75, and Coefficient Of Variation of (763.02). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Plus Therapeutics, as well as the relationship between them. Please check Plus Therapeutics market risk adjusted performance and treynor ratio to decide if Plus Therapeutics is priced some-what accurately, providing market reflects its current price of 0.23 per share. As Plus Therapeutics appears to be a penny stock we also advise to check out its jensen alpha numbers.
Plus Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Plus, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to PlusPlus Therapeutics' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Plus Therapeutics Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 5.5 | Buy | 4 | Odds |
Most Plus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Plus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Plus Therapeutics, talking to its executives and customers, or listening to Plus conference calls.
What growth prospects exist in Biotechnology sector? Can Plus capture new markets? Factors like these will boost the valuation of Plus Therapeutics. Anticipated expansion of Plus directly elevates investor willingness to pay premium valuations. Valuation analysis balances hard financial data with qualitative growth assessments. While each Plus Therapeutics valuation metric matters, prioritizing which indicators carry greater predictive weight remains essential.
Earnings Share (0.96) | Revenue Per Share | Quarterly Revenue Growth (0.04) | Return On Assets | Return On Equity |
The market value of Plus Therapeutics is measured differently than its book value, which is the value of Plus that is recorded on the company's balance sheet. Investors also form their own opinion of Plus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Plus Therapeutics' true underlying value. Investment professionals apply varied valuation frameworks to compute inherent worth and acquire positions when market prices trade at discounts to calculated value. Because Plus Therapeutics' market value can be influenced by many factors that don't directly affect Plus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Plus Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Plus Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Plus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Plus Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Plus Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Plus Therapeutics.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in Plus Therapeutics on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Plus Therapeutics or generate 0.0% return on investment in Plus Therapeutics over 90 days. Plus Therapeutics is related to or competes with NextCure, Boundless Bio, TAO Synergies, Q32 Bio, Verrica Pharmaceuticals, AN2 Therapeutics, and Jasper Therapeutics. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercia... More
Plus Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Plus Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Plus Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 48.3 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 8.93 |
Plus Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Plus Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Plus Therapeutics' standard deviation. In reality, there are many statistical measures that can use Plus Therapeutics historical prices to predict the future Plus Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (1.06) | |||
| Total Risk Alpha | (1.44) | |||
| Treynor Ratio | (0.37) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Plus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Plus Therapeutics February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.36) | |||
| Mean Deviation | 4.8 | |||
| Coefficient Of Variation | (763.02) | |||
| Standard Deviation | 6.98 | |||
| Variance | 48.75 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (1.06) | |||
| Total Risk Alpha | (1.44) | |||
| Treynor Ratio | (0.37) | |||
| Maximum Drawdown | 48.3 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 8.93 | |||
| Skewness | (2.25) | |||
| Kurtosis | 11.56 |
Plus Therapeutics Backtested Returns
Plus Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.15, which implies the firm had a -0.15 % return per unit of risk over the last 3 months. Plus Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Plus Therapeutics' Variance of 48.75, risk adjusted performance of (0.09), and Coefficient Of Variation of (763.02) to confirm the risk estimate we provide. The company holds a Beta of 2.49, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Plus Therapeutics will likely underperform. At this point, Plus Therapeutics has a negative expected return of -1.05%. Please make sure to check Plus Therapeutics' maximum drawdown and rate of daily change , to decide if Plus Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.7 |
Very good reverse predictability
Plus Therapeutics has very good reverse predictability. Overlapping area represents the amount of predictability between Plus Therapeutics time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Plus Therapeutics price movement. The serial correlation of -0.7 indicates that around 70.0% of current Plus Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.7 | |
| Spearman Rank Test | -0.59 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Plus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Plus Therapeutics Technical Analysis
The output start index for this execution was fifty with a total number of output elements of eleven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Plus Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Plus Therapeutics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Plus Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Plus Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Plus Therapeutics price pattern first instead of the macroeconomic environment surrounding Plus Therapeutics. By analyzing Plus Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Plus Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Plus Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2025 | 2026 (projected) | Payables Turnover | 0.1 | 0.0982 | Days Of Inventory On Hand | 30.62 | 29.09 |
Plus Therapeutics February 5, 2026 Technical Indicators
Most technical analysis of Plus help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Plus from various momentum indicators to cycle indicators. When you analyze Plus charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.36) | |||
| Mean Deviation | 4.8 | |||
| Coefficient Of Variation | (763.02) | |||
| Standard Deviation | 6.98 | |||
| Variance | 48.75 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (1.06) | |||
| Total Risk Alpha | (1.44) | |||
| Treynor Ratio | (0.37) | |||
| Maximum Drawdown | 48.3 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 8.93 | |||
| Skewness | (2.25) | |||
| Kurtosis | 11.56 |
Plus Therapeutics February 5, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Plus stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 408,687 | ||
| Daily Balance Of Power | (0.50) | ||
| Rate Of Daily Change | 0.96 | ||
| Day Median Price | 0.23 | ||
| Day Typical Price | 0.23 | ||
| Price Action Indicator | 0.00 |
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.